A Phase III, Randomised, Double-blind, Multi-centre, Parallel Group Study to Compare the Efficacy of Cediranib (AZD2171, RECENTIN) (30 mg) When Added to Gemcitabine and Cisplatin versus the Efficacy of Placebo When Added to Gemcitabine and Cisplatin in Patients with Locally Advanced or Metastatic (Stage IIIb/IV) Non Small Cell Lung Cancer.
Latest Information Update: 27 Jul 2020
At a glance
- Drugs Cediranib (Primary) ; Cisplatin; Gemcitabine
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors AstraZeneca
Most Recent Events
- 27 Jul 2020 This trial is completed in United Kingdom according to European Clinical Trials Database record.
- 13 Aug 2011 New trial record
- 10 May 2011 This trial is recruiting in Czech Republic and discontinued in United Kingdom.